Background: Apixaban has been increasingly utilized for various FDA-approved indications,
including stroke prevention and venous thromboembolism (VTE) treatment in patients with …

Background: In 2014, the United States Food and Drug Administration approved a labeling
change for apixaban to include recommendations for patients with severe renal impairment …

Vitamin K antagonists (VKA) remain the primary treatment of nonvalvular atrial fibrillation
(NVAF) in patients with end-stage renal disease on dialysis for stroke prevention. However …

Background: Current guidelines and literature suggest apixaban may be used in patients
with severe kidney disease and atrial fibrillation (AF) for stroke and systemic embolism risk …

Background: Current guidelines make no specific recommendations on the selection of
direct oral anticoagulants for the prevention and treatment of venous thromboembolism in …

Background This review aims to evaluate the safety and efficacy of apixaban vs. vitamin K
antagonists (VKAs) in patients on dialysis. Methods All types of studies published on …

Background Apixaban is a direct-acting oral anticoagulant (DOAC) used to treat or prevent
thromboembolic events. Renal impairment limits DOAC use. Studies supporting Food and …

Background: Warfarin has been the cornerstone of therapy for patients with stage 4 and 5
chronic kidney disease (CKD) requiring anticoagulation. These patients were omitted from …

Background: Patients with chronic kidney disease (CKD) are at a high risk of stroke-related
morbidity, mortality, and bleeding. However, the overall risk/benefit of anticoagulant therapy …

Essentials• The safety of apixaban in patients on dialysis is currently debated.• Bleeding
events were retrospectively compared for dialysis patients on warfarin vs apixaban.• Overall …